Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/32541
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorAgulló, Laura-
dc.contributor.authorEscorial, Mónica-
dc.contributor.authorOrutño, Samantha-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorSandoval, Juan-
dc.contributor.authorMargarit, César-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-07-18T09:58:58Z-
dc.date.available2024-07-18T09:58:58Z-
dc.date.created2024-06-04-
dc.identifier.citationAddict Biol. 2024 Jul;29(7):e13422es_ES
dc.identifier.issn1355-6215-
dc.identifier.urihttps://hdl.handle.net/11000/32541-
dc.description.abstractOpioid use disorder (OUD) is a multifaceted condition influenced by sex, genetic and environmental factors that could be linked with epigenetic changes. Understanding how these factors interact is crucial to understand and address the development and progression of this disorder. Our aim was to elucidate different potential epigenetic and genetic mechanisms between women and men that correlate with OUD under real-world pain unit conditions. Associations between analgesic response and the DNA methylation level of the opioid mu receptor (OPRM1) gene (CpG sites 1–5 selected in the promoter region) were evaluated in 345 long opioid-treated chronic non cancer pain: cases with OUD (n = 67) and controls (without OUD, n = 278). Cases showed younger ages, low employment status and quality of life, but higher morphine equivalent daily dose and psychotropic use, compared to the controls. The patients with OUD showed a significant decrease in OPRM1 DNA methylation, which correlated with clinical outcomes like pain relief, depression and different adverse events. Significant differences were found at the five CpG sites studied for men, and exclusively in women for CpG site 3, in relation to OUD diagnosis. These findings support the importance of epigenetics and sex as biological variables to be considered toward efficient OUD understanding and therapy developmentes_ES
dc.formatapplication/pdfes_ES
dc.format.extent8es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectchronic paines_ES
dc.subjectDNA methylationes_ES
dc.subjectepigeneticses_ES
dc.subjectopioid use disorderes_ES
dc.subjectOPRM1 genees_ES
dc.subjectpharmacogeneticses_ES
dc.subjectsex differenceses_ES
dc.subject.otherCDU: Ciencias aplicadas: Medicina: Farmacología. Terapéutica. Toxicología. Radiología-
dc.titleEpigenetic and sex differences in opioid use disorder in chronic pain: A real-world study linked with OPRM1 DNA methylationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1111/adb.13422es_ES
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica


Vista previa

Ver/Abrir:
 Epigenetic and sex differences in opioid use disorder in chronic.pdf

1,22 MB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.